AVENIO ctDNA Expanded Kits

Overview

The AVENIO ctDNA Expanded Kit is a next-generation sequencing (NGS) liquid biopsy assay with a 77 gene panel containing genes in U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers. The Expanded Kit is a pan-cancer assay that’s specially optimized for lung cancer and colorectal cancer (CRC).

Features and Benefits of AVENIO ctDNA Expanded Kits

• Contains genes in the U.S. National Comprehensive Cancer Network (NCCN) Guidelines¹ and emerging cancer biomarkers
• All four mutation classes (SNVs, indels, fusions and CNVs) in a single assay
• Exceptional analytical performance supported by integrated digital error suppression (iDES) strategies combining molecular barcodes with in silico error suppression techniques^2,3
• Includes reagents, bioinformatics and software
• Streamlined, end-to-end workflow from extraction to analysis and reporting in five days

Product Highlights

Accurate detection of all four classes of mutations with high sensitivity and specificity^2,3

• >99% sensitivity for all four classes of mutations
• >99% positive predictive value (PPV) for indels, fusions and CNVs, and >98% PPV for SNVs

View performance data showing >96 to >99% sensitivity and >98 to >99% PPV for all four classes of mutations using the AVENIO ctDNA Expanded Kit.

View the detailed gene list for the AVENIO Expanded Panel (part 1)

The AVENIO ctDNA Expanded Kit is one of three assays in the AVENIO ctDNA assay portfolio. Learn more about the 17-gene AVENIO ctDNA Targeted Kit for guideline-driven tumor profiling or the 197-gene AVENIO ctDNA Surveillance Kit for longitudinal tumor burden monitoring.